Investigational drug · Phase 2
AG-221
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Leukemia, Myeloid, Acute.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
48
Any phase or sponsor naming "AG-221"
First trial start
2016
Jun 3, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AG-221", any sponsor or status.
Conditions studied
As listed on its trial records.
- Leukemia, Myeloid, Acute
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "AG-221" as an intervention, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyPivotal-lookingActive, not recruiting
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT03839771 · 968 participants (planned) · Start Mar 1, 2019 · Primary completion Apr 17, 2027
Drug: AG-120; Placebo for AG-120 and 2 more · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
Sites: Adelaide, Australia; Brisbane, Australia; Camperdown, Australia · 181 sites in all
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT02813135 · 472 participants (planned) · Start Aug 3, 2016 · Primary completion Feb 2031
Drug: Ribociclib; Topotecan and 22 more · For: Pediatric Cancer
Sites: Copenhagen, Denmark; Villejuif, France; Angers, France · 23 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT01915498 · 345 participants · Start Aug 27, 2013 · Primary completion Jul 25, 2019
Drug: Enasidenib · For: Hematologic Neoplasms
Sites: Duarte, California; Stanford, California; Aurora, Colorado · 24 sites in all
- An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02577406 · 319 participants · Start Dec 30, 2015 · Primary completion Mar 17, 2020
Drug: AG-221; Azacitidine and 2 more · For: Leukemia, Myeloid; Isocitrate Dehydrogenase
Sites: Miami, Florida; Orlando, Florida; Chicago, Illinois · 93 sites in all
- Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04603001 · 260 participants (planned) · Start Nov 19, 2020 · Primary completion Jul 3, 2023
Drug: LY3410738; Venetoclax and 1 more · For: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia (CMML) and 1 more
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 37 sites in all
- Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 MutationActive, not recruiting
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT02632708 · 153 participants · Start Dec 31, 2015 · Primary completion Dec 13, 2018
Drug: AG-120; AG-221 and 5 more · For: Newly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS) and 2 more
Sites: Duarte, California; Los Angeles, California; Aurora, Colorado · 17 sites in all
- Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaPivotal-lookingActive, not recruiting
Actinium PharmaceuticalsIndustry
NCT02665065 · 153 participants · Start Jun 2016 · Primary completion Jun 2022
Drug: Iomab-B; Conventional Care · For: Acute Myeloid Leukemia; Leukemia, Acute Myeloid; Myeloid Leukemia, Acute and 6 more
Sites: Gilbert, Arizona; New Haven, Connecticut; Washington D.C., District of Columbia · 24 sites in all
- A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction ChemotherapyPivotal-lookingActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT02677922 · 130 participants · Start Jun 3, 2016 · Primary completion Aug 2, 2018
Drug: AG-120; Azacitidine and 1 more · For: Leukemia, Myeloid, Acute
Sites: Duarte, California; New Haven, Connecticut; Chicago, Illinois · 49 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- State of the Art of IDH Inhibitors: Emerging Questions and Perspectives.
de Lima JAL, Lima LM · Anticancer Agents Med Chem 2026
- Compatibility of cold herb CP and hot herb AZ in Huanglian Ganjiang decoction alleviates colitis mice through M1/M2 macrophage polarization balance via PDK4-mediated glucose metabolism reprogramming.
Li Y, Liu C, Wang Y, et al. · Chin J Nat Med 2025
- RNA binding motif protein 45-mediated phosphorylation enhances protein stability of ASCT2 to promote hepatocellular carcinoma progression.
Du D, Qin M, Shi L, et al. · Oncogene 2023
- Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells.
Palau A, Segerberg F, Lidschreiber M, et al. · Leukemia 2023
- Design, synthesis, AML activity and molecular modeling of novel IDH2 inhibitors.
Jin R, Tang T, Zhou S, et al. · Bioorg Chem 2023
- Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers.
Yao K, Liu H, Yin J, et al. · J Exp Clin Cancer Res 2021
Also in development for Leukemia, Myeloid, Acute
- BleximenibJNJ-75276617Phase 32 trials
Johnson & Johnson (Janssen) · Acute Leukemia, Leukemia, Myeloid, Acute
- CusatuzumabOV-1001, JNJ-74494550Phase 22 trials
OncoVerity, Inc. · Leukemia, Myeloid, Acute
- AG-120Phase 21 trial
Bristol Myers Squibb · Leukemia, Myeloid, Acute
- BG1805Phase 21 trial
Guangzhou Bio-gene Technology Co., Ltd · Leukemia, Myeloid, Acute
- TuspetinibHM43239Phase 21 trial
Aptose Biosciences Inc. · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.